Month: January 2026

Release – Graham Corporation Acquires FlackTek, Strengthening Mission-Critical Engineered Products Platform

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GHM

January 26, 2026 7:30am EST Download as PDF

  • Establishes advanced mixing and material processing as the third pillar to Graham’s mission-critical engineered products portfolio
  • Adds proprietary mixing products, utilizing bladeless dual asymmetric centrifugal principles, which builds off the strong foundation in vacuum, heat transfer, and high-speed turbomachinery
  • Strong overlap across Graham’s end markets and customers; Defense, Energy & Process and Space with new sub-markets including battery, medical, nuclear, semiconductor, and personal care
  • Enhances long-term growth through disruptive technology, recurring consumables, and aftermarket opportunities in established and emerging end-markets

BATAVIA, N.Y.–(BUSINESS WIRE)– Graham Corporation (NYSE: GHM) (“GHM” or “the Company”), a global leader in the design and manufacture of mission-critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space markets, today announced the acquisition of FlackTek Manufacturing, LLC and FlackTek Sales, LLC (“FlackTek”), a pioneer in advanced mixing and material processing solutions.

The acquisition adds advanced materials processing as a third core platform for Graham, alongside Graham Manufacturing, specializing in vacuum & heat transfer, and Barber-Nichols, specializing in turbomachinery. FlackTek will operate as a wholly owned subsidiary of Graham Corporation, maintaining its headquarters in Louisville, Colorado with a satellite location in Greenville, South Carolina, and will be integrated into Graham’s financial, compliance, and operational infrastructure.

Under the terms of the transaction, Graham acquired 100% of the equity of FlackTek for a purchase price of $35 million, which was paid 85% in cash and 15% using 75,818 shares of Graham’s common stock, along with the potential to earn an additional $25 million in future performance-based cash earnouts over four years beginning with the Company’s fiscal year 2027, based upon achieving progressively increasing adjusted EBITDA performance targets each year. The base purchase price represents approximately 12x FlackTek’s projected adjusted EBITDA for 2026.

“FlackTek represents a highly strategic addition to Graham’s mission-critical product portfolio and directly aligns with our long-term vision to build differentiated, technology-led platforms,” said Matthew J. Malone, President and Chief Executive Officer of Graham Corporation. “The fundamental physics behind advanced mixing align closely with Graham’s core competencies in vacuum, heat transfer, and turbomachinery, enabling new opportunities to solve complex materials processing challenges for customers across defense, aerospace, and industrial markets. It’s unique that the FlackTek product portfolio impacts the full value chain from the mine to final assembly with applicability in upstream, midstream, and downstream applications.”

Matt Gross, Chief Executive Officer of FlackTek, said, “Joining Graham marks an exciting new chapter for FlackTek. Graham’s engineering heritage, manufacturing expertise, and strong presence in our core end markets provide an ideal platform to accelerate our growth while preserving the innovation and customer focus that define our culture. I look forward to continuing to lead the FlackTek team as part of Graham and continue to expand the impact of our technology together.”

Overview of FlackTek

Recognized as a leader in high-performance, bladeless centrifugal mixing, FlackTek designs and manufactures advanced mixing systems, accessories, consumables, and material processing solutions built on its proprietary product portfolio. Headquartered in Louisville, Colorado, FlackTek maintains a strong domestic manufacturing footprint complemented by an established international distribution network.

FlackTek’s technology delivers highly repeatable, precision mixing with significantly faster cycle times, minimal entrained air, reduced downtime between batches, consistency in production, and reduced heat transfer compared to traditional bladed methods. These performance advantages are critical in applications where material integrity and consistency are paramount. As a result, FlackTek’s systems are trusted by a global customer base that includes leading OEMs, research and development centers, defense laboratories, and industrial manufacturers serving adhesives, sealants, functional coatings, composites, electronics, and other advanced materials markets.

The company has successfully expanded its portfolio beyond laboratory-scale systems into larger, highly differentiated platforms, most notably the MEGA™ system, enabling customers to scale advanced materials processing from R&D through pilot and into production environments.

With approximately $30 million in annualized revenue, FlackTek has built a growing installed base that generates recurring demand for consumables, accessories, and services, enhancing revenue visibility and durability. FlackTek’s technical excellence, mixing effectiveness and efficiency, service responsiveness, innovation, and reliability, position it well for continued growth through both expanded end-market penetration and broader sales channel development.

FlackTek Strategic Rationale

The acquisition of FlackTek meaningfully expands Graham’s ability to solve complex customer challenges that increasingly demand integrated solutions spanning rotating machinery, vacuum environments, thermal management, and advanced materials processing. FlackTek’s technology sits naturally alongside Barber-Nichols’ turbomachinery and Graham Manufacturing’s vacuum and heat transfer systems, creating a more comprehensive engineered solutions platform.

FlackTek adds a proven and defensible product portfolio with a shared customer base and an installed footprint that extends across the full value chain, from upstream to downstream production and quality control. Its mixing systems are process-critical and market-agnostic, serving defense, energetics, oil & gas, food, battery, aerospace and space, medical, and other industrial applications where precision, repeatability, and consistency drive value.

By adding a differentiated engineered systems business with strong intellectual property and recurring revenue characteristics, the acquisition is expected to enhance margins, deepen customer relationships, and unlock cross-platform innovation opportunities across Graham’s defense, energy & process, and space end markets.

Other Transaction Details

The cash portion of the consideration was funded through a combination of cash on hand and borrowings under the Company’s existing credit facilities.

In connection with the acquisition, Graham amended its credit agreement to enhance financial flexibility and support continued investment in organic growth initiatives and opportunistic acquisitions. The amendment increased the Company’s revolving credit facility from $50 million to $80 million, providing additional capacity to execute its capital allocation strategy and future growth.

Following the closing of the transaction, Graham’s pro forma leverage ratio is approximately 1.2x, consistent with the Company’s disciplined capital allocation framework and targeted leverage profile. The overall transaction structure, including the upfront consideration and a performance-based earnout component, aligns with Graham’s long-term financial objectives while preserving balance sheet strength and liquidity.

FlackTek’s Chief Executive Officer, Matt Gross, will join Graham’s leadership team as Vice President and General Manager and will continue to lead the FlackTek business, ensuring continuity of operations and strategic execution.

The Company has published a supplemental presentation in connection with the announced acquisition. This presentation is available under the “Events & Presentations” section of the Company’s website at ir.grahamcorp.com. The Company will provide additional details on the acquisition and update its fiscal 2026 outlook on its Fiscal 2026 Third Quarter earnings call scheduled for 11:00 am ET on Friday, February 6, 2026.

About Graham Corporation

Graham is a global leader in the design and manufacture of mission critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space industries. Graham Corporation and its family of global brands are built upon world-renowned engineering expertise in vacuum and heat transfer, cryogenic pumps, and turbomachinery technologies, as well as its responsive and flexible service and the unsurpassed quality customers have come to expect from the Company’s products and systems. Graham Corporation routinely posts news and other important information on its website, grahamcorp.com, where additional information on Graham Corporation and its businesses can be found.

Safe Harbor Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “positions,” “will,” and other similar words. All statements addressing operating performance, events, or developments that Graham Corporation expects or anticipates will occur in the future, including but not limited to, profitability of future projects and the business, its ability to deliver to plan, realization of benefits from the acquisition of FlackTek, the integration and operation of FlackTek, and the effect of the FlackTek acquisition on our growth are forward-looking statements. Because they are forward-looking, they should be evaluated in light of important risk factors and uncertainties. These risk factors and uncertainties are more fully described in Graham Corporation’s most recent Annual Report filed with the Securities and Exchange Commission (the “SEC”), included under the heading entitled “Risk Factors”, and in other reports filed with the SEC.

Should one or more of these risks or uncertainties materialize or should any of Graham Corporation’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Graham Corporation’s forward-looking statements. Except as required by law, Graham Corporation disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this news release.

For more information:
Christopher J. Thome
Vice President – Finance and CFO
Phone: (585) 343-2216
CThome@graham-mfg.com

Tom Cook
Investor Relations
(203) 682-8250
Tom.Cook@icrinc.com

Source: Graham Corporation

Released January 26, 2026

The GEO Group (GEO) – Expansion of Credit Facility

Posted on by slightbourne@noblecapitalmarkets.com


Monday, January 26, 2026

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Credit Facility. The GEO Group amended its Credit Agreement, increasing GEO’s revolving credit facility to $550 million from a prior $450 million. The increase was effective as of January 20th. The increase provides the Company with additional financial flexibility, in our view, to further invest in growth opportunities and/or increase the share repurchase activity.

Share Repurchases. Recall, back in November, GEO announced an expansion of its share repurchase authorization to $500  million and extended the expiration date to  December 31, 2029. As of  November 6, 2025, the Company had approximately $458 million of repurchase authorization available under the share repurchase program. At the current price, the $100 million, if all used to repurchase shares, would further reduce the share count by approximately 5.38 million shares.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Winter Storm Puts U.S. Energy Companies Under Pressure as Demand, Prices Surge

Posted on by slightbourne@noblecapitalmarkets.com

A sweeping winter storm moving across the United States is not only threatening travel and power reliability for millions of Americans, but also placing intense pressure on energy companies as demand spikes and infrastructure faces severe stress. From Texas to the Northeast, utilities, power generators, and natural gas suppliers are being tested by the combination of extreme weather and soaring consumption.

In Texas, where freezing rain and snow are expected to arrive by Friday evening, the state’s energy sector faces one of its most critical moments in years. Electricity demand is projected to surge to more than 84 gigawatts Monday morning, according to the Electric Reliability Council of Texas (ERCOT), nearing the state’s all-time record. For power generators, this represents both an opportunity for higher revenues and a risk of operational failure if equipment is unable to perform in icy conditions.

Utilities operating on the Texas grid remain under scrutiny following the catastrophic winter storm of 2021. While significant investments have been made to winterize power plants and natural gas infrastructure, ice accumulation and extreme cold could still disrupt fuel supply, particularly for gas-fired power plants that dominate the state’s generation mix. Any outages would not only strain the grid but expose utilities to reputational damage and regulatory consequences.

Natural gas producers and pipeline operators are already seeing dramatic price impacts. Futures prices have climbed more than 70% this week, while spot prices in some regions have surged to extraordinary levels. For gas producers, especially those with exposure to spot markets, the price spikes could translate into short-term windfall revenues. However, pipeline constraints and weather-related disruptions may limit their ability to fully capitalize on higher prices, highlighting the importance of infrastructure resilience.

In the Northeast and Mid-Atlantic, power markets operated by PJM Interconnection are preparing for sustained high demand as heavy snowfall and frigid temperatures move in. PJM has asked generators to delay maintenance and ensure maximum availability through early next week. Power prices in the region have already surged, benefiting generators with reliable capacity while increasing costs for utilities and retail energy suppliers that must purchase electricity at elevated rates.

The storm also arrives amid growing structural strain on the U.S. grid. The PJM region is home to the country’s highest concentration of data centers, particularly in northern Virginia, where electricity demand is rising rapidly due to the expansion of artificial intelligence and cloud computing. The combination of extreme weather and data-driven demand underscores the challenges facing utilities tasked with balancing reliability, affordability, and growth.

Energy infrastructure companies, including those providing grid services, battery storage, and demand-response solutions, may also come into sharper focus. In recent years, flexible demand programs—where large consumers reduce usage during peak periods—have played a critical role in avoiding widespread outages. Companies offering these services stand to gain as grid operators increasingly rely on non-traditional tools to maintain stability.

As the storm unfolds, investors and policymakers alike will be watching how energy companies perform under stress. The event could reinforce the case for continued investment in grid modernization, weatherization, and diversified energy sources—areas likely to shape the energy sector’s outlook long after the snow melts.

Release – MustGrow Closes $2.0 Million Non-Brokered LIFE Offering

Posted on by slightbourne@noblecapitalmarkets.com

January 23, 2026 – MustGrow Biologics Corp. (TSXV: MGRO; OTC: MGROF; FRA: 0C0) (the “Company” or “MustGrow”), is pleased to announce: the closing of its previously announced non-brokered private placement of 4,000,000 units of the Company (each, a “Unit”) at a price of $0.50 per Unit for gross proceeds of $2,000,000 (the “LIFE Offering”).

Each Unit consists of (i) one common share of the Company (a “Share”) and (ii) one common share purchase warrant (a “Warrant”). Each whole Warrant will be exercisable for a period of 60 months from the date of closing and will entitle the holder thereof to purchase one additional Share (a “Warrant Share”) at an exercise price of $0.70 per Warrant Share.

The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSanteTM, inventory for agricultural products to sell via its Canadian distribution platform NexusBioAg, and working capital and general corporate purposes.

The Units sold pursuant to the LIFE Offering were offered pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 – Prospectus Exemptions as modified by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption.

Subject to the rules and policies of the TSX Venture Exchange (the “TSXV”), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws.

As consideration for services, certain eligible finders received (i) an aggregate cash fee equal to $105,000, being 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by such finders; and (ii) 210,000 non-transferable common share purchase warrants (the “Finder’s Warrants”) representing 6.0% of the aggregate number of Shares forming part of the Units issued to investors introduced to the Company by the finders. Each Finder’s Warrant will entitle its holder to purchase one Share (a “Finder Warrant Share”) at a price of $0.70 per Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws.

The LIFE Offering remains subject to final approval of the TSXV.

Market Awareness Services and Investor Relations Agreements

The Company has entered into market awareness and investor awareness agreements (the “Awareness Agreements”) with partners to bring visibility and awareness to MustGrow over the next 12 months: Apaton Finance GmbH (“Apaton”), Ellernstr. 34, 30175 Hanover, Germany, www.apaton.com. The objective of this partnership is to further enhance the reach, visibility, and relevance of the Company’s corporate communications. As part of the cooperation, Apaton will produce editorial and video content in both German and English. This content will be distributed directly and indirectly via news portals, search engines, and AI-supported platforms, newsletter, thereby increasing the accessibility of the Company’s information for interested investors. The brand-building initiative, combining fact-based reporting with emotionally engaging video storytelling, has been agreed for a fixed term of 12 months, commencing in February 1, 2026, with a total budget of EUR 120,000.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 110 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 62.9 million common shares issued and outstanding and 77.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements in this news release, including statements about: the intended use of proceeds from the LIFE Offering and TSXV’s final approval of the LIFE Offering and the Agreements, the outcomes resulting from the Agreements and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: risks relating to the Company’s receipt of final approval from the TSXV and those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release. © 2026 MustGrow Biologics Corp. All rights reserved.

Release – Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Posted on by slightbourne@noblecapitalmarkets.com

January 23, 2026

Data from eight participants continue to support safety and tolerability profile of tegoprubart

Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months

IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona.

There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months.

Details on the poster presentation are below:

Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen
Poster: #62
Session Title: Poster Session B
Date: Friday, January 23, 2026, from 5:45 – 7:15 p.m. PT

Following the presentation, a copy of the poster will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

Release – SKYX Announces Pricing of $25 Million Registered Direct Offering at $2.50 per share of Common Stock from One Fundamental Institutional Investor

Posted on by slightbourne@noblecapitalmarkets.com

MIAMI, Jan. 23, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive smart home platform technology company with over 100 pending and issued patents globally and 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today announced that it has entered into a securities purchase agreement with one fundamental institutional investor to raise $25 million of gross proceeds via a registered direct offering.

Under the terms of the securities purchase agreement, the Company will issue, for an aggregate purchase price of $25 million, a total of 10 million shares of common stock, at a purchase price of $2.50 per share with no warrants. The closing of the offering is subject to customary closing conditions and is expected to close on or about January 26, 2026. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Roth Capital Partners is acting as the exclusive placement agent for the offering.

A shelf registration statement on Form S-3 (File No. 333-271698) relating to the securities being offered was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 5, 2023 and declared effective on May 12, 2023. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the shelf registration statement. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained on the SEC’s website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660 or by email at rothecm@roth.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SKYX Platforms Corp.

SKYX Platforms Corp. (NASDAQ: SKYX) is a technology platform company focused on making homes and buildings safe, advanced, and smart as the new standard. As electricity is present in every home and building, SKYX is developing disruptive plug & play technologies designed to modernize traditional electrical infrastructure while improving safety, functionality, and ease of use.

The Company holds over 100 issued and pending U.S. and global patents and owns 60 lighting and home décor websites serving both retail and professional markets. SKYX’s platform emphasizes high-quality design, simplicity, and enhanced safety, with applications intended for every room in residential, commercial, hospitality, and institutional buildings worldwide.

SKYX’s technologies support recurring revenue opportunities through product interchangeability, upgrades, AI-enabled services, monitoring, and subscriptions. The Company follows a “razor-and-blades” model, anchored by its advanced ceiling electrical outlet platform and an expanding portfolio of plug & play smart home products, including lighting, recessed and down lights, emergency and exit signage, ceiling fans, chandeliers, indoor and outdoor fixtures, and themed lighting solutions. Its plug & play technology enables rapid installation in high-rise buildings and hotels, reducing deployment timelines from months to days.

SKYX estimates its U.S. total addressable market at approximately $500 billion, with more than 4.2 billion ceiling applications in the U.S. alone. Revenue streams are expected to include product sales, licensing, royalties, subscriptions, monitoring services, and the sale of global country rights.

For more information, please visit our website at https://skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements
Certain statements made in this press release are not based on historical facts but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target,” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to completion, size and timing of the offering, the Company’s intended use of proceeds from the offering, the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contact:
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com

Release – Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Posted on by slightbourne@noblecapitalmarkets.com

January 23, 2026

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by RTW Investments, with additional participation from new and existing investors.

Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses and anticipates that the net proceeds will extend the company’s cash runway into the fourth quarter of 2026.

Oppenheimer & Co. acted as the sole book-running manager for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-278774) previously filed with the Securities and Exchange Commission (the “SEC”) on April 18, 2024, which became effective on May 1, 2024. The offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement relating to and describing the terms of the offering has been filed with the SEC. Copies of the prospectus supplement and the accompanying base prospectus relating to the offering, may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding Ocugen’s expectations regarding the anticipated use of proceeds. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including the Company’s expected cash runway and various other factors. These and other risks and uncertainties are more fully described in our periodic filings with the SEC, including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by applicable law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, changed circumstances or otherwise, after the date of this press release.

Ocugen Contact:

Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@Ocugen.com

Kuya Silver (KUYAF) – Mine Development and Balance Sheet Strength Support 2026 Ramp-Up

Posted on by slightbourne@noblecapitalmarkets.com


Friday, January 23, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fourth Quarter Performance. The company mined 1,999 tonnes of mineralized material and processed 1,570 tonnes. Average processed grades were 6.0 oz/t silver (186.6 g/t), 1.40% lead, and 1.10% zinc, or 8.5 oz/t silver equivalent (264 g/t). Recoveries averaged 73.3% for silver, 79.1% for lead, and 57.1% for zinc. Metal processed included 7,724 ounces of silver, 18 tonnes of lead, and 15 tonnes of zinc. Sales included 5,441 ounces of silver, 15 tonnes of lead, and 8 tonnes of zinc, representing 6,194 silver-equivalent ounces, with silver contributing 88%. 

Private Placement Financing. Kuya closed a brokered private placement raising gross proceeds of C$25.5 million. The company intends to pursue either the acquisition of an operating plant near the mine or the construction of a plant at the Bethania site to vertically integrate silver concentrate production. As mine production expands toward the Phase 1 target of 350 tonnes per day, Kuya expects more consistent processing, improved silver recoveries, and the recovery of minor gold and copper currently lost in the toll-milling process.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Vehicle Group (CVGI) – Some Green Shoots? Updated Estimates

Posted on by slightbourne@noblecapitalmarkets.com


Friday, January 23, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updated Estimates. We tweaked our fourth quarter 2025 estimates after speaking with management. The changes do not impact our belief in the investment case for Commercial Vehicle Group. We maintained our revenue estimate at $146 million. Gross margin has been lowered to 10.3% from 11% previously. We are now estimating an adjusted net loss of $5 million, or $0.15 per share. Adjusted EBITDA is now $2.8 million. For the full year, we are at revenue of $640.2 million and adjusted EBITDA of $18.3 million.

Green Shoots? Recent data from FTR and ACT could indicate an improved Class 8 truck environment in 2026, although we would need to see multiple months of positive developments before jumping in with both feet. According to FTR, December Class 8 truck orders of 42,200 units were the highest level since October 2022. Meanwhile, ACT raised its expectation for Class 8 production in 2026 to 246,000 units, up from a prior 205,000, and nearly flat with 2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Silver Surges Past $100 an Ounce as Speculation, Tight Supply Fuel Historic Rally

Posted on by slightbourne@noblecapitalmarkets.com

Silver prices surged past the $100-per-ounce mark on Friday, reaching a milestone few market participants believed possible just a year ago. The move caps an extraordinary rally driven by speculative enthusiasm, strong investment demand, and years of structural supply deficits, while raising growing concerns about overheating and the risk of a sharp correction.

Spot silver climbed more than 5% on the day to trade above $101 per troy ounce, extending a powerful advance that began in 2025. The metal has gained roughly 40% since the start of 2026, following a staggering 147% surge last year—its strongest annual performance in more than four decades. Silver’s rally has been amplified by gold’s parallel rise, with gold prices also hitting record highs as geopolitical uncertainty and inflation hedging continue to dominate investor psychology.

Market analysts say silver’s lower absolute price compared to gold has made it especially attractive to retail investors, fueling momentum-driven buying. Waves of demand for physical bars and coins, combined with strong inflows into physically backed exchange-traded funds, have tightened available supply and intensified price moves.

The gold-to-silver ratio, a closely watched metric, has dropped sharply. It now takes just 50 ounces of silver to buy one ounce of gold—the lowest level in 14 years. Historically, such extremes have often preceded periods of underperformance for silver, suggesting the metal’s outperformance relative to gold may be stretched.

Fundamentally, the picture is more mixed. While silver benefits from its dual role as both a precious and industrial metal—used extensively in electronics, solar panels, and manufacturing—some analysts argue prices have outrun underlying demand. Bank of America estimates a fundamentally justified silver price closer to $60 an ounce, pointing to signs that solar-related demand may have peaked and that elevated prices could begin to curb industrial consumption.

Supply constraints, however, remain a key pillar of support. The silver market has recorded five consecutive years of structural deficits, a trend expected to continue into 2026. Recycling accounts for nearly 20% of global supply, but limited high-grade refining capacity has slowed the return of scrap metal to the market, preventing inventories from rebuilding quickly.

Although stockpiles in London and U.S. futures markets have partially recovered from last year’s lows, they remain well below historical norms. This reduced buffer has left the market more vulnerable to sudden surges in demand.

Looking ahead, analysts expect volatility to remain elevated. With some easing in physical market tightness and the possibility of profit-taking after the explosive rally, a pullback appears increasingly likely. Still, silver’s dramatic move above $100 underscores a broader reality: in an environment of geopolitical risk, supply constraints, and speculative fervor, precious metals remain firmly in the spotlight—and silver is leading the charge.

Trump’s NATO Deal Opens Greenland to US Missiles and Mining

Posted on by slightbourne@noblecapitalmarkets.com

President Donald Trump’s abrupt de-escalation of tariff threats against Europe came with a significant strategic tradeoff: a NATO-centered framework that would dramatically expand the United States’ military and economic footprint in Greenland. While the agreement stops short of addressing sovereignty, it lays the groundwork for US missile deployments, expanded NATO activity in the Arctic, and American access to critical mineral resources—moves aimed squarely at countering Russian and Chinese influence in the region.

The outlines of the deal emerged after Trump met NATO Secretary General Mark Rutte at the World Economic Forum in Davos. According to European officials briefed on the talks, the framework focuses on Arctic security cooperation, including stationing US missile systems in or around Greenland and granting the US preferential mining rights to prevent Chinese firms from gaining a foothold. In exchange, Trump agreed to suspend planned tariffs on European nations that had threatened to fracture transatlantic relations.

For NATO, the agreement reflects growing urgency around the Arctic. Melting ice is opening new sea lanes that could provide strategic access between the Pacific and Atlantic, raising alarms about potential military and commercial exploitation by rival powers. Rutte has emphasized that Greenland sits at the center of this shift, making it critical to alliance defense planning. Strengthening NATO’s presence there would help monitor emerging routes, protect undersea infrastructure, and deter hostile activity.

Crucially, the framework avoids any discussion of transferring sovereignty over Greenland, a semi-autonomous territory of Denmark. That omission marks a notable shift from Trump’s earlier rhetoric, which repeatedly suggested US acquisition of the island. Danish Prime Minister Mette Frederiksen has been firm that Greenland is not for sale, stressing that any arrangement must respect international law and Danish sovereignty. NATO officials have echoed that position, framing the deal as a security partnership rather than a territorial negotiation.

Still, Trump has portrayed the outcome as a decisive win. In interviews following the Davos meeting, he claimed the US would gain “total access” to Greenland for security purposes, with no clear time limits. While the details remain vague, officials say the framework could involve updating a 1951 defense agreement that already grants the US broad latitude to operate militarily in Greenland under NATO auspices.

Beyond missiles and bases, mining rights represent a key economic dimension. Greenland holds significant deposits of rare earths and other critical minerals essential to advanced manufacturing, clean energy, and defense systems. By securing access for US or allied companies, the deal would aim to keep Chinese interests—currently dominant in global rare-earth supply chains—out of the Arctic resource race.

The agreement, however, is far from finalized. Danish leaders have cautioned that NATO’s secretary general has no mandate to negotiate on Denmark’s behalf, and Greenland’s own government remains wary. Trump’s earlier threats and aggressive language have fueled anxiety among Greenlanders, with local leaders warning residents to remain vigilant even if the likelihood of conflict is low.

For investors and policymakers alike, the emerging framework underscores how geopolitics, critical minerals, and defense strategy are converging in the Arctic. Whether the deal evolves into a durable alliance agreement or stalls amid political backlash will shape not only NATO’s northern posture, but also the balance of power in one of the world’s fastest-changing strategic frontiers.

Release – V2X and Bell Advance to Phase II of the US Army’s Flight School Next Competition

Posted on by aweinsoff@channelchek.com

Research News and Market Data on VVX

January 22, 2026

RESTON, Va., Jan. 22, 2026 /PRNewswire/ — V2X Inc. (NYSE: VVX) is proud to announce its advancement to Phase II of the US Army’s Flight School Next (FSN) competition, as part of the Bell Textron Inc. led team alongside a remarkable network of industry teammates. This demonstrates V2X’s commitment to supporting the future of Army aviation training and preparing the next generation of mission-ready pilots through cutting-edge solutions.

FSN represents the Army’s initiative to revolutionize pilot training by leveraging advanced technologies and innovative methodologies to produce highly-skilled aviators capable of meeting the dynamic needs of modern missions. Having successfully completed Phase I, V2X, with its proven capabilities in immersive training environments and data-driven advancements, joins Bell and other contributors to collaboratively design solutions that will shape the future of aviation education.

“Advancing to Phase II alongside Bell and our teammates is a significant step forward in our shared effort to empower Army aviation with pioneering training methods,” said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. “Together, we’re driving innovation that will fundamentally transform pilot development and readiness, ensuring mission success in any environment.”

 As part of Bell’s FSN team, V2X brings to the table decades of expertise in simulation-based training, logistics, sustainment, and advanced technologies to enhance flight training operations. Through these collaborative efforts, V2X will integrate state-of-the-art solutions, offering soldiers an adaptive, efficient, and immersive learning experience that streamlines traditional aviation training processes. In Phase II of the FSN competition, V2X and Bell will continue refining the training architecture and exploring new approaches to address the Army’s readiness goals.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,100 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact 
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Marketing and Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-and-bell-advance-to-phase-ii-of-the-us-armys-flight-school-next-competition-302667150.html

SOURCE V2X, Inc.

Release – SelectQuote to Release Fiscal Second Quarter 2026 Earnings on February 5

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SLQT

01/22/2026

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fiscal second quarter 2026 financial results before market open on Thursday, February 5, 2026. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 5, 2026) at 8:00 am ET to discuss the results.

We encourage interested parties to access the live webcast of the event via our investor relations website https://ir.selectquote.com/investor-home/default.aspx or via this link.

For those interested in dialing into the conference call, please register using this link. After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at least 10 minutes before the start of the call.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com

Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com

Source: SelectQuote, Inc.